You are here : Home > Research entities > Antibody Engineering and immunogenicity

Antibody Engineering and immunogenicity

Published on 12 August 2022

​Group leader

Hervé Nozach
01 69 08 42 15

The Antibody Engineering and Immunogenicity team of DMTS/SIMoS develops new antibody-based ligands for various applications, whether therapeutic, imaging or diagnostic. The team is particularly interested in designing high affinity antibodies with controlled selectivity but also with low immunogenicity to allow administration in humans while limiting the risks of immunogenicity.
The team has developed tools for molecular engineering of proteins coupling a high-throughput screening method, the Yeast Surface Display, with high-throughput NGS sequencing methods (1). In particular, it implements the Deep Mutational Scanning approach aimed at identifying the main amino acids in the protein sequence that have a functional role. The DMS data allow us to understand the protein/protein interfaces (such as epitopes or paratopes) (2, 3). They are also used to guide the engineering of optimized molecules, notably for affinity maturation or antibody selectivity engineering.

​Main Publications

  1. Sivelle, C., R. Sierocki, K. Ferreira-Pinto, S. Simon, B. Maillere, and H. Nozach. 2018. Fab is the most efficient format to express functional antibodies by yeast surface display. mAbs 10: 720-729.
  2. Sierocki, R., B. Jneid, M. L. Orsini Delgado, M. Plaisance, B. Maillere, H. Nozach, and S. Simon. 2021. An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections. PLoS neglected tropical diseases 15: e0009231.
  3. Bouleau, A., H. Nozach, S. Dubois, D. Kereselidze, C. Chevaleyre, C. I. Wang, M. J. Evans, V. Lebon, B. Maillere, and C. c. Truillet. 2021. Optimizing immunoPET imaging of tumor PD-L1 expression: pharmacokinetics, biodistribution and dosimetric comparisons of (89)Zr-labeled anti-PD-L1 antibody formats. J Nucl Med